

Date: 29 April 2025

Ref. No.: TCPCL/SEC/2025-26/00007

To,
The General Manager,
Corporate relationship department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

The Manager,
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex, Bandra(E),
Mumbai-400 051

Scrip Code: 543321

Scrip Symbol: TATVA

Subject: Fund raising by issuance of debt securities by Large Corporates

Ref.: Chapter XII of SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, as updated on April 13, 2022 and SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023.

Dear Sir/Madam,

Pursuant to SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, as updated on April 13, 2022 and SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, we hereby confirm that Tatva Chintan Pharma Chem Limited is not a Large Corporate as per the applicability criteria given under the above mentioned SEBI circulars.

The details as required in respect of Initial Disclosure are enclosed as Annexure - XII – A.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Tatva Chintan Pharma Chem Limited

Ishwar Nayi
Company Secretary and Compliance Officer
M. No.: A37444

Encl.: As above

Annexure - XII – A

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate
(To be submitted to the Stock Exchange(s) within 30 days from the beginning of the FY)

Sr. No.	Particulars	Details
1.	Name of the Company	TATVA CHINTAN PHARMA CHEM LIMITED
2.	CIN	L24232GJ1996PLC029894
3.	Outstanding borrowing of company as on 31 March 2025, as applicable (in Rs. crore)	Rs. 0.64 Crores
4.	Highest Credit Rating During the previous FY along with name of the Credit Rating Agency	CRISIL A-/Negative (Long Term Rating) CRISIL A2+ (Short Term Rating) Agency – CRISIL Ratings Limited
5.	Name of stock exchange* in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	Not Applicable

We confirm that **we are not a Large Corporate** as per the applicability criteria given under the Chapter XII of SEBI Operational circular dated August 10, 2021, as updated on April 13, 2022 and SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023.

For Tatva Chintan Pharma Chem Limited

Ishwar Nayi
Company Secretary
M. No.: A37444
Tel: +91 75748 48533
E-mail: cs@tatvachintan.com

Ashok Bothra
Chief Financial Officer
Tel: +91 75748 48533
E-mail: finance@tatvachintan.com

Date – 29/04/2025

*Note: In terms paragraph of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.